Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1

Kim,Dong-Wook; Ko,Seon   Mi; Jeon,Young-Joo; Noh,Young-Woock; Choi,Nag-Jin; Cho,Sung-Dae; Moon,Hong Seop; Cho,Young  Sik; Shin,Jae-Chen; Park,Seon-Min; Seo,Kang  Seok; Choi,Ji-Young; Chae,Jung-Il; Shim,Jung-Hyun

doi:10.3892/ijo.2013.2028

Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1

Authors:
- Dong-Wook Kim
- Seon Mi Ko
- Young-Joo Jeon
- Young-Woock Noh
- Nag-Jin Choi
- Sung-Dae Cho
- Hong Seop Moon
- Young Sik Cho
- Jae-Chen Shin
- Seon-Min Park
- Kang Seok Seo
- Ji-Young Choi
- Jung-Il Chae
- Jung-Hyun Shim
View Affiliations

Affiliations: Department of Oral Pharmacology, School of Dentistry and Institute of Dental Bioscience, BK21 project, Chonbuk National University, Jeonju, Republic of Korea, Graduate School and Department of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea, Department of Animal Science, College of Agricultural and Life Science, Chonbuk National University, Jeonju, Republic of Korea, Department of Oral Pathology, Chonbuk National University, Jeonju, Republic of Korea, College of Pharmacy, Mokpo National University, Jeonnam, Republic of Korea, Department of Pharmacy, Keimyung University, Daegu, Republic of Korea, Pohang Center for Evaluation of Biomaterials, Pohang, Gyeongbuk, Republic of Korea, Department of Animal Science and Technology, Sunchon National University, Suncheon, Republic of Korea, Medical Proteomics Research Center, KRIBB, Daejeon, Republic of Korea
Published online on: July 22, 2013 https://doi.org/10.3892/ijo.2013.2028
Pages: 1103-1110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Honokiol (HK), a novel plant-derived natural product, is a physiologically activated compound with polyphenolic structure, and has been identified to function as an anticancer agent. It has been widely used in several diseases as a traditional medicine for a long time. We investigated whether HK could show anticancer effects on two oral squamous cell lines (OSCCs), HN-22 and HSC-4. We demonstrated that HK-treated cells showed dramatic reduction in cell growth and apoptotic cell morphologies. Intriguingly, the transcription factor specificity protein 1 (Sp1) was significantly inhibited by HK in a dose-dependent manner. Furthermore, we checked changes in cell cycle regulatory proteins and anti-apoptotic proteins at the molecular level, which are known as Sp1 target genes. The important key regulators in the cell cycle such as p27 and p21 were up-regulated by HK-mediated down-regulation of Sp1, whereas anti-apoptotic proteins including Mcl-1 and survivin were decreased, resulting in caspase-dependent apoptosis. Taken together, results from this study suggest that HK could modulate Sp1 transactivation and induce apoptotic cell death through the regulation of cell cycle and suppression of anti‑apoptotic proteins. In addition, HK may be used in cancer prevention and therapies to improve the clinical outcome as an anticancer drug.

View Figures

View References

1.	Hamada T, Wakamatsu T, Miyahara M, et al: MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer. 130:1768–1776. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009. View Article : Google Scholar
3.	Newman DJ and Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 75:311–335. 2012.PubMed/NCBI
4.	Fried LE and Arbiser JL: Honokiol, a multifunctional anti-angiogenic and antitumor agent. Antioxid Redox Signal. 11:1139–1148. 2009. View Article : Google Scholar
5.	Fujita M, Itokawa H and Sashida Y: Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants. Yakugaku Zasshi. 93:429–434. 1973.(In Japanese).
6.	Teng CM, Chen CC, Ko FN, et al: Two antiplatelet agents from Magnolia officinalis. Thromb Res. 50:757–765. 1988. View Article : Google Scholar : PubMed/NCBI
7.	Liou KT, Lin SM, Huang SS, Chih CL and Tsai SK: Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med. 69:130–134. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Lo YC, Teng CM, Chen CF, Chen CC and Hong CY: Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol. 47:549–553. 1994.
9.	Kuribara H, Kishi E, Hattori N, Yuzurihara M and Maruyama Y: Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of magnolia. Phytother Res. 13:593–596. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Battle TE, Arbiser J and Frank DA: The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 106:690–697. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Shigemura K, Arbiser JL, Sun SY, et al: Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 109:1279–1289. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Garcia A, Zheng Y, Zhao C, et al: Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 14:4267–4274. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Deng J, Qian Y, Geng L, et al: Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 28:1458–1464. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Li Z, Liu Y, Zhao X, et al: Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 140:95–102. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Bai X, Cerimele F, Ushio-Fukai M, et al: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 278:35501–35507. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Sheu ML, Chiang CK, Tsai KS, et al: Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med. 44:2043–2050. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Lee J, Jung E, Park J, et al: Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med. 71:338–343. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Tse AK, Wan CK, Shen XL, Yang M and Fong WF: Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem Pharmacol. 70:1443–1457. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Li L and Davie JR: The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat. 192:275–283. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Hirano T, Gotoh M and Oka K: Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 55:1061–1069. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Yang SE, Hsieh MT, Tsai TH and Hsu SL: Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol. 63:1641–1651. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Abdelrahim M, Smith R III, Burghardt R and Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64:6740–6749. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Ishibashi H, Nakagawa K, Onimaru M, et al: Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res. 60:6531–6536. 2000.
24.	Kong LM, Liao CG, Fei F, Guo X, Xing JL and Chen ZN: Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci. 101:1463–1470. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Chuang JY, Wu CH, Lai MD, Chang WC and Hung JJ: Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer. 125:2066–2076. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Choi ES, Shim JH, Jung JY, et al: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci. 102:742–748. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Shim JH, Shin JA, Jung JY, et al: Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev. 20:102–111. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Davie JR, He S, Li L, et al: Nuclear organization and chromatin dynamics - Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul. 48:189–208. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Grinstein E, Jundt F, Weinert I, Wernet P and Royer HD: Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21:1485–1492. 2002. View Article : Google Scholar : PubMed/NCBI
30.	Chen F, Zhang F, Rao J and Studzinski GP: Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res. 20:661–667. 2000.PubMed/NCBI
31.	Blume SW, Snyder RC, Ray R, Thomas S, Koller CA and Miller DM: Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest. 88:1613–1621. 1991. View Article : Google Scholar : PubMed/NCBI
32.	Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 3:222–225. 1997. View Article : Google Scholar : PubMed/NCBI
33.	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
35.	Murray AW: Recycling the cell cycle: cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
36.	Albanese C, Johnson J, Watanabe G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 270:23589–23597. 1995. View Article : Google Scholar : PubMed/NCBI
37.	Lee RJ, Albanese C, Stenger RJ, et al: pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem. 274:7341–7350. 1999.
38.	Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
39.	Weinstein IB: Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem (Suppl). 25:23–28. 1996. View Article : Google Scholar : PubMed/NCBI
40.	Li F: Survivin study: what is the next wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
41.	Xu R, Zhang P, Huang J, Ge S, Lu J and Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Chun JY, Hu Y, Pinder E, Wu J, Li F and Gao AC: Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther. 6:2572–2580. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Yoon JH, Werneburg NW, Higuchi H, et al: Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res. 62:6500–6505. 2002.PubMed/NCBI
44.	Okaro AC, Deery AR, Hutchins RR and Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol. 54:927–932. 2001. View Article : Google Scholar : PubMed/NCBI
45.	Akgul C: Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 66:1326–1336. 2009. View Article : Google Scholar : PubMed/NCBI
46.	Andersson Y, Juell S and Fodstad O: Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-pseudomonas exotoxin a immunotoxin. Int J Cancer. 112:475–483. 2004. View Article : Google Scholar : PubMed/NCBI
47.	Chetoui N, Sylla K, Gagnon-Houde JV, et al: Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res. 6:42–52. 2008. View Article : Google Scholar : PubMed/NCBI
48.	Wei SH, Dong K, Lin F, et al: Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 62:1055–1064. 2008. View Article : Google Scholar : PubMed/NCBI